Metabolic comorbidities in Cushing's syndrome

European Journal of Endocrinology

Volumn 173, Issue 4, 2015, Pages M133-M157

  Ferraù, Francesco ^a   Korbonits, Márta ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ADENYLATE KINASE; ADIPOCYTOKINE; ENDOCANNABINOID; GHRELIN; GLUCOCORTICOID; GROWTH HORMONE; HYDROCORTISONE; LIM DOMAIN ONLY 3 PROTEIN; LIM PROTEIN; MINERALOCORTICOID RECEPTOR; PASIREOTIDE; UNCLASSIFIED DRUG; HUMAN GROWTH HORMONE; INSULIN; SOMATOMEDIN C;

ADIPOSE TISSUE; APPETITE; BLOOD VESSEL INJURY; COMORBIDITY; CONFERENCE PAPER; CUSHING DISEASE; CUSHING SYNDROME; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ENZYME ACTIVITY; FATTY LIVER; GLUCOSE METABOLISM; GROWTH HORMONE RELEASE; HUMAN; HYPERTENSION; NONHUMAN; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; VASCULARIZATION; BODY FAT DISTRIBUTION; DYSLIPIDEMIAS; GLUCONEOGENESIS; HYPERGLYCEMIA; LIPID METABOLISM; METABOLISM; OBESITY, ABDOMINAL; PHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; BODY FAT DISTRIBUTION; COMORBIDITY; CUSHING SYNDROME; DYSLIPIDEMIAS; GLUCOCORTICOIDS; GLUCONEOGENESIS; HUMAN GROWTH HORMONE; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; OBESITY, ABDOMINAL; SIGNAL TRANSDUCTION;

EID: 84942771683     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0354     Document Type: Conference Paper

References (224)

1. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M & Lombardi G. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. Journal of Clinical Endocrinology and Metabolism 1999 84 2664-2672. (doi:10.1210/jcem.84.8.5896).
2. Etxabe J & Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clinical Endocrinology 1994 40 479-484. (doi:10.1111/j.1365-2265.1994.tb02486.x).
3. Neary NM, Booker OJ, Abel BS, Matta JR, Muldoon N, Sinaii N, Pettigrew RI, Nieman LK & Gharib AM. Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography. Journal of Clinical Endocrinology and Metabolism 2013 98 2045-2052. (doi:10.1210/jc.2012-3754).
4. Feelders RA, Pulgar SJ, Kempel A & Pereira AM. The burden of Cushing's disease: clinical and health-related quality of life aspects. European Journal of Endocrinology 2012 167 311-326. (doi:10.1530/EJE-11-1095).
5. Resmini E, Minuto F, Colao A & Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetologica 2009 46 85-95. (doi:10.1007/s00592-009-0112-9).
6. Pecori-Giraldi F, Moro M, Cavagnini F & Study Group on the Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of Endocrinology. Gender-related differences in the presentation and course of Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2003 88 1554-1558. (doi:10.1210/jc.2002-021518).
7. Giordano C, Guarnotta V, Pivonello R, Amato MC, Simeoli C, Ciresi A, Cozzolino A & Colao A. Is diabetes in Cushing's syndrome only a consequence of hypercortisolism? European Journal of Endocrinology 2014 170 311-319. (doi:10.1530/EJE-13-0754).
8. Mancini T, Kola B, Mantero F, Boscaro M & Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology 2004 61 768-777. (doi:10.1111/j.1365-2265.2004.02168.x).
9. Boscaro M & Arnaldi G. Approach to the patient with possible Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2009 94 3121-3131. (doi:10.1210/jc.2009-0612).
10. Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European Journal of Endocrinology 2011 165 383-392. (doi:10.1530/EJE-11-0272).
11. Shimon I. Screening for Cushing's syndrome: is it worthwhile? Pituitary 2015 18 201-205. (doi:10.1007/s11102-015-0634-9).
12. Tabarin A & Perez P. Pros and cons of screening for occult Cushing syndrome. Nature Reviews. Endocrinology 2011 7 445-455. (doi:10.1038/nrendo.2011.51).
13. Terzolo M, Reimondo G, Chiodini I, Castello R, Giordano R, Ciccarelli E, Limone P, Crivellaro C, Martinelli I, Montini M et al. Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. Journal of Clinical Endocrinology and Metabolism 2012 97 3467-3475. (doi:10.1210/jc.2012-1323).
14. Giordano R, Guaraldi F, Berardelli R, Karamouzis I, D'Angelo V, Marinazzo E, Picu A, Ghigo E & Arvat E. Glucose metabolism in patients with subclinical Cushing's syndrome. Endocrine 2012 41 415-423. (doi:10.1007/s12020-012-9628-9).
15. Di-Dalmazi G, Pasquali R, Beuschlein F & Reincke M. Subclinical Hypercortisolism: A State, A Syndrome, Or A Disease? European Journal of Endocrinology 2015 173. (doi:10.1530/EJE-15-0272).
16. Di-Dalmazi G, Vicennati V, Rinaldi E, Morselli-Labate AM, Giampalma E, Mosconi C, Pagotto U & Pasquali R. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. European Journal of Endocrinology 2012 166 669-677. (doi:10.1530/EJE-11-1039).
17. Kim BY, Chun AR, Kim KJ, Jung CH, Kang SK, Mok JO & Kim CH. Clinical characteristics and metabolic features of patients with adrenal incidentalomas with or without subclinical Cushing's syndrome. Endocrinology and Metabolism 2014 29 457-463. (doi:10.3803/EnM.2014.29.4.457).
18. Vassilatou E, Vryonidou A, Ioannidis D, Paschou SA, Panagou M & Tzavara I. Bilateral adrenal incidentalomas differ from unilateral adrenal incidentalomas in subclinical cortisol hypersecretion but not in potential clinical implications. European Journal of Endocrinology 2014 171 37-45. (doi:10.1530/EJE-13-0848).
19. Ivovic M, Marina LV, Vujovic S, Tancic-Gajic M, Stojanovic M, Radonjic NV, Gajic M, Soldatovic I & Micic D. Nondiabetic patients with either subclinical Cushing's or nonfunctional adrenal incidentalomas have lower insulin sensitivity than healthy controls: clinical implications. Metabolism: Clinical and Experimental 2013 62 786-792. (doi:10.1016/j.metabol.2012.12.006).
20. Muscogiuri G, Sorice GP, Prioletta A, Mezza T, Cipolla C, Salomone E, Giaccari A, Pontecorvi A & Della-Casa S. The size of adrenal incidentalomas correlates with insulin resistance. Is there a causeeffect relationship? Clinical Endocrinology 2011 74 300-305. (doi:10.1111/j.1365-2265.2010.03928.x).
21. Reincke M, Fassnacht M, Vath S, Mora P & Allolio B. Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocrine Research 1996 22 757-761.
22. Androulakis II, Kaltsas GA, Kollias GE, Markou AC, Gouli AK, Thomas DA, Alexandraki KI, Papamichael CM, Hadjidakis DJ & Piaditis GP. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. Journal of Clinical Endocrinology and Metabolism 2014 99 2754-2762. (doi:10.1210/jc.2013-4064).
23. Peppa M, Boutati E, Koliaki C, Papaefstathiou N, Garoflos E, Economopoulos T, Hadjidakis D & Raptis SA. Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: a cause-effect relationship? Metabolism: Clinical and Experimental 2010 59 1435-1441. (doi:10.1016/j.metabol.2010.01.007).
24. Mazziotti G, Gazzaruso C & Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends in Endocrinology and Metabolism 2011 22 499-506. (doi:10.1016/j.tem.2011.09.001).
25. Wu Z, Jiao P, Huang X, Feng B, Feng Y, Yang S, Hwang P, Du J, Nie Y, Xiao G & Xu H. MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice. Journal of Clinical Investigation 2010 120 3901-3911. (doi:10.1172/JCI43250).
26. Nader N, Ng SS, Wang Y, Abel BS, Chrousos GP & Kino T. Liver x receptors regulate the transcriptional activity of the glucocorticoid receptor: implications for the carbohydrate metabolism. PLoS ONE 2012 7 e26751. (doi:10.1371/journal.pone.0026751).
27. Bernal-Mizrachi C, Weng S, Feng C, Finck BN, Knutsen RH, Leone TC, Coleman T, Mecham RP, Kelly DP & Semenkovich CF. Dexamethasone induction of hypertension and diabetes is PPAR-a dependent in LDL receptor-null mice. Nature Medicine 2003 9 1069-1075. (doi:10.1038/nm898).
28. Ruzzin J, Wagman AS & Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia 2005 48 2119-2130. (doi:10.1007/s00125-005-1886-0).
29. Patti ME, Brambilla E, Luzi L, Landaker EJ & Kahn CR. Bidirectional modulation of insulin action by amino acids. Journal of Clinical Investigation 1998 101 1519-1529. (doi:10.1172/JCI1326).
30. Abdul-Ghani MA & De-Fronzo RA. Pathogenesis of insulin resistance in skeletal muscle. Journal of Biomedicine & Biotechnology 2010 2010 476279. (doi:10.1155/2010/476279).
31. Kershaw EE & Flier JS. Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology and Metabolism 2004 89 2548-2556. (doi:10.1210/jc.2004-0395).
32. Tamura Y, Kawao N, Yano M, Okada K, Okumoto K, Chiba Y, Matsuo O & Kaji H. Role of plasminogen activator inhibitor-1 in glucocorticoid-induced diabetes and osteopenia in mice. Diabetes 2015 64 2194-2206. (doi:10.2337/db14-1192).
33. Hansen KB, Vilsboll T, Bagger JI, Holst JJ & Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. Journal of Clinical Endocrinology and Metabolism 2010 95 3309-3317. (doi:10.1210/jc.2010-0119).
34. Van-Raalte DH, Nofrate V, Bunck MC, van-Iersel T, Elassaiss Schaap J, Nassander UK, Heine RJ, Mari A, Dokter WH & Diamant M. Acute and 2-week exposure to prednisolone impair different aspects of b-cell function in healthy men. European Journal of Endocrinology 2010 162 729-735. (doi:10.1530/EJE-09-1034).
35. Rafacho A, Goncalves-Neto LM, Santos-Silva JC, Alonso-Magdalena P, Merino B, Taboga SR, Carneiro EM, Boschero AC, Nadal A & Quesada I. Pancreatic a-cell dysfunction contributes to the disruption of glucose homeostasis and compensatory insulin hypersecretion in glucocorticoid- Treated rats. PLoS ONE 2014 9 e93531. (doi:10.1371/journal.pone.0093531).
36. Yi CX, Foppen E, Abplanalp W, Gao Y, Alkemade A, la-Fleur SE, Serlie MJ, Fliers E, Buijs RM, Tschop MH et al. Glucocorticoid signaling in the arcuate nucleus modulates hepatic insulin sensitivity. Diabetes 2012 61 339-345. (doi:10.2337/db11-1239).
37. Trementino L, Appolloni G, Concettoni C, Cardinaletti M, Boscaro M & Arnaldi G. Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome. European Journal of Endocrinology 2012 166 35-42. (doi:10.1530/EJE-11-0722).
38. Godang K, Ueland T & Bollerslev J. Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing's syndrome. European Journal of Endocrinology 1999 141 126-131. (doi:10.1530/eje.0.1410126).
39. Wei J & Karsenty G. An overview of the metabolic functions of osteocalcin. Reviews in Endocrine & Metabolic Disorders, 2015. (doi:10.1007/s11154-014-9307-7).
40. Lekva T, Bollerslev J, Sahraoui A, Scholz H, Boyum H, Evang JA, Godang K, Aukrust P & Ueland T. Thioredoxin interacting protein is a potential regulator of glucose and energy homeostasis in endogenous Cushing's syndrome. PLoS ONE 2013 8 e64247. (doi:10.1371/journal.pone.0064247).
41. De-Leo M, Cozzolino A, Colao A & Pivonello R. Subclinical Cushing's syndrome. Best Practice & Research. Clinical Endocrinology & Metabolism 2012 26 497-505. (doi:10.1016/j.beem.2012.02.001).
42. Iacobone M, Citton M, Viel G, Boetto R, Bonadio I, Mondi I, Tropea S, Nitti D & Favia G. Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing's syndrome. Surgery 2012 152 991-997. (doi:10.1016/j.surg.2012.08.054).
43. Perysinakis I, Marakaki C, Avlonitis S, Katseli A, Vassilatou E, Papanastasiou L, Piaditis G & Zografos GN. Laparoscopic adrenalectomy in patients with subclinical Cushing syndrome. Surgical Endoscopy 2013 27 2145-2148. (doi:10.1007/s00464-012-2730-5).
44. Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, Feltrin D, Igreja SC, Ajodha S, Harvey-White J et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB Journal 2008 22 1672-1683. (doi:10.1096/fj.07-094144).
45. Kola B, Christ-Crain M, Lolli F, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB & Korbonits M. Changes in adenosine 5'-monophosphate- Activated protein kinase as a mechanismof visceral obesity in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2008 93 4969-4973. (doi:10.1210/jc.2008-1297).
46. Bortolini M, Wright MB, Bopst M & Balas B. Examining the safety of PPAR agonists - current trends and future prospects. Expert Opinion on Drug Safety 2013 12 65-79. (doi:10.1517/14740338.2013.741585).
47. Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M et al. Effects of chronic administration of PPAR-g ligand rosiglitazone in Cushing's disease. European Journal of Endocrinology 2004 151 173-178. (doi:10.1530/eje.0.1510173).
48. Chon S, Riveline JP, Blondeau B & Gautier JF. Incretin-based therapy and pancreatic b cells. Diabetes & Metabolism 2014 40 411-422. (doi:10.1016/j.diabet.2014.05.003).
49. Avogaro A, Vigili de Kreutzenberg S & Fadini GP. Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. Current Diabetes Reports 2014 14 483. (doi:10.1007/s11892-014-0483-3).
50. Colao A, De-Block C, Gaztambide MS, Kumar S, Seufert J & Casanueva FF. Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Pituitary 2014 17 180-186. (doi:10.1007/s11102-013-0483-3).
51. Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet- Rudelli C, Delemer B, Tabarin A, Bisot-Locard S & Verges B. Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. Diabetes & Metabolism 2013 39 34-41. (doi:10.1016/j.diabet.2012.10.005).
52. Berthon BS, MacDonald-Wicks LK & Wood LG. A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans. Nutrition Research 2014 34 179-190. (doi:10.1016/j.nutres.2013.12.006).
53. Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP & Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. American Journal of Physiology 1996 271 E317-E325.
54. Castonguay TW. Glucocorticoids as modulators in the control of feeding. Brain Research Bulletin 1991 27 423-428. (doi:10.1016/0361-9230(91)90136-8).
55. Scerif M, Fuzesi T, Thomas JD, Kola B, Grossman AB, Fekete C & Korbonits M. CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus. Journal of Endocrinology 2013 219 79-88. (doi:10.1530/JOE-13-0192).
56. Terzolo M, Reimondo G, Ali A, Bovio S, Daffara F, Paccotti P & Angeli A. Ectopic ACTH syndrome: molecular bases and clinical heterogeneity. Annals of Oncology 2001 12 (Suppl 2) S83-S87. (doi:10.1093/annonc/12.suppl-2.S83).
57. Dallman MF, Pecoraro NC & la-Fleur SE. Chronic stress and comfort foods: self-medication and abdominal obesity. Brain, Behavior, and Immunity 2005 19 275-280. (doi:10.1016/j.bbi.2004.11.004).
58. Di S, Malcher-Lopes R, Halmos KC & Tasker JG. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. Journal of Neuroscience 2003 23 4850-4857.
59. Kahn BB, Alquier T, Carling D & Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 2005 1 15-25. (doi:10.1016/j.cmet.2004.12.003).
60. Shimizu H, Arima H, Watanabe M, Goto M, Banno R, Sato I, Ozaki N, Nagasaki H & Oiso Y. Glucocorticoids increase neuropeptide Y and agouti-related peptide gene expression via adenosine monophosphate- Activated protein kinase signaling in the arcuate nucleus of rats. Endocrinology 2008 149 4544-4553. (doi:10.1210/en.2008-0229).
61. Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R & Pfeiffer EF. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. Journal of Clinical Investigation 1989 84 1663-1670. (doi:10.1172/JCI114345).
62. Tomlinson JJ, Boudreau A, Wu D, Atlas E & Hache RJ. Modulation of early human preadipocyte differentiation by glucocorticoids. Endocrinology 2006 147 5284-5293. (doi:10.1210/en.2006-0267).
63. Lee MJ, Gong DW, Burkey BF & Fried SK. Pathways regulated by glucocorticoids in omental and subcutaneous human adipose tissues: a microarray study. American Journal of Physiology. Endocrinology and Metabolism 2011 300 E571-E580. (doi:10.1152/ajpendo.00231.2010).
64. Tomlinson JJ, Boudreau A, Wu D, Abdou Salem H, Carrigan A, Gagnon A, Mears AJ, Sorisky A, Atlas E & Hache RJ. Insulin sensitization of human preadipocytes through glucocorticoid hormone induction of forkhead transcription factors. Molecular Endocrinology 2010 24 104-113. (doi:10.1210/me.2009-0091).
65. Peckett AJ, Wright DC & Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism: Clinical and Experimental 2011 60 1500-1510. (doi:10.1016/j.metabol.2011.06.012).
66. Ayala-Sumuano JT, Velez-delValle C, Beltran-Langarica A, Marsch- Moreno M, Hernandez-Mosqueira C & Kuri-Harcuch W. Glucocorticoid paradoxically recruits adipose progenitors and impairs lipid homeostasis and glucose transport in mature adipocytes. Scientific Reports 2013 3 2573. (doi:10.1038/srep02573).
67. Veilleux A, Laberge PY, Morency J, Noel S, Luu-The V & Tchernof A. Expression of genes related to glucocorticoid action in human subcutaneous and omental adipose tissue. Journal of Steroid Biochemistry and Molecular Biology 2010 122 28-34. (doi:10.1016/j.jsbmb.2010.02.024).
68. Rebuffe-Scrive M, Bronnegard M, Nilsson A, Eldh J, Gustafsson JA & Bjorntorp P. Steroid hormone receptors in human adipose tissues. Journal of Clinical Endocrinology and Metabolism 1990 71 1215-1219. (doi:10.1210/jcem-71-5-1215).
69. Hazlehurst JM, Gathercole LL, Nasiri M, Armstrong MJ, Borrows S, Yu J, Wagenmakers AJ, Stewart PM & Tomlinson JW. Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue in vivo. Journal of Clinical Endocrinology and Metabolism 2013 98 1631-1640. (doi:10.1210/jc.2012-3523).
70. Macfarlane DP, Forbes S & Walker BR. Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. Journal of Endocrinology 2008 197 189-204. (doi:10.1677/JOE-08-0054).
71. Geer EB, Islam J & Buettner C. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinology and Metabolism Clinics of North America 2014 43 75-102. (doi:10.1016/j.ecl.2013.10.005).
72. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M & Stewart PM. 11b-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrine Reviews 2004 25 831-866. (doi:10.1210/er.2003-0031).
73. Morgan SA, McCabe EL, Gathercole LL, Hassan-Smith ZK, Larner DP, Bujalska IJ, Stewart PM, Tomlinson JW & Lavery GG. 11b-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. PNAS 2014 111 E2482-E2491. (doi:10.1073/pnas.1323681111).
74. Wang Y, Yan C, Liu L, Wang W, Du H, Fan W, Lutfy K, Jiang M, Friedman TC & Liu Y. 11b-hydroxysteroid dehydrogenase type 1 shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adipose tissue. American Journal of Physiology. Endocrinology and Metabolism 2015 308 E84-E95. (doi:10.1152/ajpendo.00205.2014).
75. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR & Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001 294 2166-2170. (doi:10.1126/science.1066285).
76. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR & Flier JS. Adipocyte-specific glucocorticoid inactivation protects against dietinduced obesity. Diabetes 2005 54 1023-1031. (doi:10.2337/diabetes.54.4.1023).
77. De-Kloet AD, Krause EG, Solomon MB, Flak JN, Scott KA, Kim DH, Myers B, Ulrich-Lai YM, Woods SC, Seeley RJ et al. Adipocyte glucocorticoid receptors mediate fat-to-brain signaling. Psychoneuroendocrinology 2015 56 110-119. (doi:10.1016/j.psyneuen.2015.03.008).
78. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR & Mullins JJ. Metabolic syndrome without obesity: hepatic overexpression of 11b-hydroxysteroid dehydrogenase type 1 in transgenic mice. PNAS 2004 101 7088-7093. (doi:10.1073/pnas.0305524101).
79. Tomlinson JW, Draper N, Mackie J, Johnson AP, Holder G, Wood P & Stewart PM. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. Journal of Clinical Endocrinology and Metabolism 2002 87 57-62. (doi:10.1210/jcem.87.1.8189).
80. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC & Grino M. Expression of the mRNA coding for 11b-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. Journal of Clinical Endocrinology and Metabolism 2002 87 2701-2705. (doi:10.1210/jcem.87.6.8614).
81. Mariniello B, Ronconi V, Rilli S, Bernante P, Boscaro M, Mantero F & Giacchetti G. Adipose tissue 11b-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. European Journal of Endocrinology 2006 155 435-441. (doi:10.1530/eje.1.02228).
82. Bowles NP, Karatsoreos IN, Li X, Vemuri VK, Wood JA, Li Z, Tamashiro KL, Schwartz GJ, Makriyannis AM, Kunos G et al. A peripheral endocannabinoid mechanism contributes to glucocorticoid- mediated metabolic syndrome. PNAS 2015 112 285-290. (doi:10.1073/pnas.1421420112).
83. Hirata A, Maeda N, Nakatsuji H, Hiuge-Shimizu A, Okada T, Funahashi T & Shimomura I. Contribution of glucocorticoidmineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction. Biochemical and Biophysical Research Communications 2012 419 182-187. (doi:10.1016/j.bbrc.2012.01.139).
84. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M& Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroidinduced adipogenesis. FASEB Journal 2007 21 2185-2194. (doi:10.1096/fj.06-7970com).
85. Hoppmann J, Perwitz N, Meier B, Fasshauer M, Hadaschik D, Lehnert H & Klein J. The balance between gluco- And mineralocorticoid action critically determines inflammatory adipocyte responses. Journal of Endocrinology 2010 204 153-164. (doi:10.1677/JOE-09-0292).
86. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH & Adler GK. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-g, and proinflammatory adipokines. Circulation 2008 117 2253-2261. (doi:10.1161/CIRCULATIONAHA.107.748640).
87. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T & Shimomura I. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovascular Research 2009 84 164-172. (doi:10.1093/cvr/cvp191).
88. Lee MJ & Fried SK. The glucocorticoid receptor, not the mineralocorticoid receptor, plays the dominant role in adipogenesis and adipokine production in human adipocytes. International Journal of Obesity 2014 38 1228-1233. (doi:10.1038/ijo.2014.6).
89. Kuhn E, Bourgeois C, Keo V, Viengchareun S, Muscat A, Meduri G, Le-Menuet D, Feve B & Lombes M. Paradoxical resistance to high-fat diet-induced obesity and altered macrophage polarization in mineralocorticoid receptor-overexpressing mice. American Journal of Physiology. Endocrinology and Metabolism 2014 306 E75-E90. (doi:10.1152/ajpendo.00323.2013).
90. Lindroos J, Husa J, Mitterer G, Haschemi A, Rauscher S, Haas R, GrogerM, Loewe R, Kohrgruber N, Schrogendorfer KF et al. Human but not mouse adipogenesis is critically dependent on LMO3. Cell Metabolism 2013 18 62-74. (doi:10.1016/j.cmet.2013.05.020).
91. Kong X, Yu J, Bi J, Qi H, Di W, Wu L, Wang L, Zha J, Lv S, Zhang F et al. Glucocorticoids transcriptionally regulate miR-27b expression promoting body fat accumulation via suppressing the browning of white adipose tissue. Diabetes 2015 64 393-404. (doi:10.2337/db14-0395).
92. Jacob W, Rosenzweig D, Vazquez-Martin C, Duce SL & Cohen PT. Decreased adipogenesis and adipose tissue in mice with inactivated protein phosphatase 5. Biochemical Journal 2015 466 163-176. (doi:10.1042/BJ20140428).
93. Feng B, He Q & Xu H. FOXO1-dependent up-regulation of MAP kinase phosphatase 3 (MKP-3) mediates glucocorticoid-induced hepatic lipid accumulation in mice. Molecular and Cellular Endocrinology 2014 393 46-55. (doi:10.1016/j.mce.2014.06.001).
94. Yu D. Chronic glucocorticoid exposure-induced epididymal adiposity is associated with mitochondrial dysfunction in white adipose tissue of male C57BL/6J mice. PLoS ONE 2014 9 e112628. (doi:10.1371/journal.pone.0112628).
95. Barclay JL, Agada H, Jang C, Ward M, Wetzig N & Ho KK. Effects of glucocorticoids on human brown adipocytes. Journal of Endocrinology 2015 224 139-147. (doi:10.1530/JOE-14-0538).
96. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP, Besser GM, Grossman AB & Reznek RH. Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. European Journal of Endocrinology 2003 149 561-567. (doi:10.1530/eje.0.1490561).
97. Ueland T, Kristo C, Godang K, Aukrust P & Bollerslev J. Interleukin-1 receptor antagonist is associated with fat distribution in endogenous Cushing's syndrome: a longitudinal study. Journal of Clinical Endocrinology and Metabolism 2003 88 1492-1496. (doi:10.1210/jc.2002-021030).
98. Geer EB, Shen W, Gallagher D, Punyanitya M, Looker HC, Post KD & Freda PU. MRI assessment of lean and adipose tissue distribution in female patients with Cushing's disease. Clinical Endocrinology 2010 73 469-475. (doi:10.1111/j.1365-2265.2010.03829.x).
99. Geer EB, Shen W, Strohmayer E, Post KD & Freda PU. Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. Journal of Clinical Endocrinology and Metabolism 2012 97 1702-1711. (doi:10.1210/jc.2011-3123).
100. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di-Somma C, Lombardi G & Colao A. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. Journal of Clinical Endocrinology and Metabolism 2003 88 2527-2533. (doi:10.1210/jc.2002-021558).
101. Morelli V, Reimondo G, Giordano R, Della Casa S, Policola C, Palmieri S, Salcuni AS, Dolci A, Mendola M, Arosio M et al. Long-term follow-up in adrenal incidentalomas: An Italian multicenter study. Journal of Clinical Endocrinology and Metabolism 2014 99 827-834. (doi:10.1210/jc.2013-3527).
102. Shivaprasad K, Kumar M, Dutta D, Sinha B, Mondal SA, Maisnam I, Mukhopadhyay S & Chowdhury S. Increased soluble TNF receptor-1 and glutathione peroxidase may predict carotid intima media thickness in females with Cushing's syndrome. Endocrine Practice 2015 21 286-295. (doi:10.4158/EP14399.OR).
103. Barahona MJ, Resmini E, Vilades D, Fernandez-Real JM, Ricart W, Moreno-Navarrete JM, Pons-Llado G, Leta R & Webb SM. Soluble TNFa-receptor 1 as a predictor of coronary calcifications in patients after long-term cure of Cushing's syndrome. Pituitary 2015 18 135-141. (doi:10.1007/s11102-014-0566-9).
104. Ermetici F, Malavazos AE, Corbetta S, Eller-Vainicher C, Cannavo S, Corsi MM & Ambrosi B. Soluble adhesion molecules levels in patients with Cushing's syndrome before and after cure. Journal of Endocrinological Investigation 2008 31 389-392. (doi:10.1007/BF03346381).
105. Kristo C, Ueland T, Godang K, Aukrust P & Bollerslev J. Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome. Journal of Endocrinological Investigation 2008 31 400-405. (doi:10.1007/BF03346383).
106. Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, Aroasio E, Sacchetto G, Reimondo G, Angeli A et al. Hyperhomocysteinemia in patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 3745-3751. (doi:10.1210/jc.2004-0079).
107. Faggiano A, Melis D, Alfieri R, De Martino M, Filippella M, Milone F, Lombardi G, Colao A & Pivonello R. Sulfur amino acids in Cushing's disease: insight in homocysteine and taurine levels in patients with active and cured disease. Journal of Clinical Endocrinology and Metabolism 2005 90 6616-6622. (doi:10.1210/jc.2005-0656).
108. Toja PM, Branzi G, Ciambellotti F, Radaelli P, De Martin M, Lonati LM, Scacchi M, Parati G, Cavagnini F & Pecori Giraldi F. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure. Clinical Endocrinology 2012 76 332-338. (doi:10.1111/j.1365-2265.2011.04206.x).
109. Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ & Feelders RA. Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. European Journal of Endocrinology 2010 162 331-340. (doi:10.1530/EJE-09-0621).
110. Kamenicky P, Redheuil A, Roux C, Salenave S, Kachenoura N, Raissouni Z, Macron L, Guignat L, Jublanc C, Azarine A et al. Cardiac structure and function in Cushing's syndrome: A cardiac magnetic resonance imaging study. Journal of Clinical Endocrinology and Metabolism 2014 99 E2144-E2153. (doi:10.1210/jc.2014-1783).
111. Yiu KH, Marsan NA, Delgado V, Biermasz NR, Holman ER, Smit JW, Feelders RA, Bax JJ & Pereira AM. Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. European Journal of Endocrinology 2012 166 27-34. (doi:10.1530/EJE-11-0601).
112. Alexandraki KI, Kaltsas GA, Vouliotis AI, Papaioannou TG, Trisk L, Zilos A, Korbonits M, Besser GM, Anastasakis A & Grossman AB. Specific electrocardiographic features associated with Cushing's disease. Clinical Endocrinology 2011 74 558-564. (doi:10.1111/j.1365- 2265.2011.03975.x).
113. Fallo F, Maffei P, Dalla Pozza A, Carli M, Della Mea P, Lupia M, Rabbia F & Sonino N. Cardiovascular autonomic function in Cushing's syndrome. Journal of Endocrinological Investigation 2009 32 41-45. (doi:10.1007/BF03345677).
114. Chandran DS, Ali N, Jaryal AK, Jyotsna VP & Deepak KK. Decreased autonomic modulation of heart rate and altered cardiac sympathovagal balance in patients with Cushing's syndrome: role of endogenous hypercortisolism. Neuroendocrinology 2013 97 309-317. (doi:10.1159/000345905).
115. Pivonello R, Faggiano A, Lombardi G & Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinology andMetabolism Clinics of North America 2005 34 327-339, viii. (doi:10.1016/j.ecl.2005.01.010).
116. Pirlich M, Biering H, Gerl H, Ventz M, Schmidt B, Ertl S & Lochs H. Loss of body cell mass in Cushing's syndrome: effect of treatment. Journal of Clinical Endocrinology and Metabolism 2002 87 1078-1084. (doi:10.1210/jcem.87.3.8321).
117. Ragnarsson O, Glad CA, Bergthorsdottir R, Almqvist EG, Ekerstad E, Widell H, Wangberg B & Johannsson G. Body composition and bone mineral density in women with Cushing's syndrome in remission and the association with common genetic variants influencing glucocorticoid sensitivity. European Journal of Endocrinology 2015 172 1-10. (doi:10.1530/EJE-14-0747).
118. Barahona MJ, Sucunza N, Resmini E, Fernandez-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Farrerons J & Webb SM. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2009 94 3365-3371. (doi:10.1210/jc.2009-0766).
119. Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP & Nieman LK. Effects of child- And adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: A 7-year prospective study into young adulthood. Journal of Bone and Mineral Research 2007 22 110-118. (doi:10.1359/jbmr.061010).
120. Keil MF, Graf J, Gokarn N & Stratakis CA. Anthropometric measures and fasting insulin levels in children before and after cure of Cushing syndrome. Clinical Nutrition 2012 31 359-363. (doi:10.1016/j.clnu. 2011.11.007).
121. Resmini E, Farkas C, Murillo B, Barahona MJ, Santos A, Martinez-Momblan MA, Roig O, Ybarra J, Geli C & Webb SM. Body composition after endogenous (Cushing's syndrome) and exogenous (rheumatoid arthritis) exposure to glucocorticoids. Hormone and Metabolic Research 2010 42 613-618. (doi:10.1055/s-0030-1255032).
122. London E, Rothenbuhler A, Lodish M, Gourgari E, Keil M, Lyssikatos C, de la Luz Sierra M, Patronas N, Nesterova M & Stratakis CA. Differences in adiposity in Cushing syndrome caused by PRKAR1A mutations: clues for the role of cyclic AMP signaling in obesity and diagnostic implications. Journal of Clinical Endocrinology and Metabolism 2014 99 E303-E310. (doi:10.1210/jc.2013-1956).
123. London E, Lodish M, Keil M, Lyssikatos C, de la Luz Sierra M, Nesterova M & Stratakis CA. Not all glucocorticoid-induced obesity is the same: differences in adiposity among various diagnostic groups of Cushing syndrome. Hormone and Metabolic Research 2014 46 897-903. (doi:10.1055/s-0034-1389956).
124. Debono M, Prema A, Hughes TJ, Bull M, Ross RJ &Newell-Price J. Visceral fat accumulation and postdexamethasone serum cortisol levels in patients with adrenal incidentaloma. Journal ofClinical Endocrinology and Metabolism 2013 98 2383-2391. (doi:10.1210/jc.2012-4276).
125. Libe R, Morpurgo PS, Cappiello V, Maffini A, Bondioni S, Locatelli M, Zavanone M, Beck-Peccoz P & Spada A. Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery. Clinical Endocrinology 2005 62 30-36. (doi:10.1111/j.1365-2265.2004.02169.x).
126. Shinahara M, Nishiyama M, Iwasaki Y, Nakayama S, Noguchi T, Kambayashi M, Okada Y, Tsuda M, Stenzel-Poore MP, Hashimoto K et al. Plasma adiponectin levels are increased despite insulin resistance in corticotropin-releasing hormone transgenicmice, an animal model of Cushing syndrome. Endocrine Journal 2009 56 879-886. (doi:10.1507/endocrj.K09E-038).
127. Fallo F, Scarda A, Sonino N, Paoletta A, Boscaro M, Pagano C, Federspil G & Vettor R. Effect of glucocorticoids on adiponectin: A study in healthy subjects and in Cushing's syndrome. European Journal of Endocrinology 2004 150 339-344. (doi:10.1530/eje.0.1500339).
128. Ashizawa N, Takagi M, Seto S, Suzuki S & Yano K. Serum adiponectin and leptin in a patient with Cushing's syndrome before and after adrenalectomy. Internal Medicine 2007 46 383-385. (doi:10.2169/internalmedicine.46.6142).
129. Valassi E, Biller BM, Klibanski A & Misra M. Adipokines and cardiovascular risk in Cushing's syndrome. Neuroendocrinology 2012 95 187-206. (doi:10.1159/000330416).
130. Krsek M, Silha JV, Jezkova J, Hana V, Marek J, Weiss V, Stepan JJ & Murphy LJ. Adipokine levels in Cushing's syndrome; elevated resistin levels in female patients with Cushing's syndrome. Clinical Endocrinology 2004 60 350-357. (doi:10.1111/j.1365-2265.2003.01987.x).
131. Lemke U, Krones-Herzig A, Berriel Diaz M, Narvekar P, Ziegler A, Vegiopoulos A, Cato AC, Bohl S, Klingmuller U, Screaton RA et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metabolism 2008 8 212-223. (doi:10.1016/j.cmet.2008.08.001).
132. Lavery GG, Zielinska AE, Gathercole LL, Hughes B, Semjonous N, Guest P, Saqib K, Sherlock M, Reynolds G, Morgan SA et al. Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11b-hydroxysteroid dehydrogenase type 1. Endocrinology 2012 153 3236-3248. (doi:10.1210/en.2012-1019).
133. Li G, Hernandez-Ono A, Crooke RM, Graham MJ & Ginsberg HN. Effects of antisense-mediated inhibition of 11b-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. Journal of Lipid Research 2011 52 971-981. (doi:10.1194/jlr.M013748).
134. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP, Besser GM, Grossman AB & Reznek RH. Hepatic steatosis in Cushing's syndrome: A radiological assessment using computed tomography. European Journal of Endocrinology 2003 149 543-548. (doi:10.1530/eje. 0.1490543).
135. Tauchmanova L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S & Lombardi G. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. Journal of Clinical Endocrinology and Metabolism 2002 87 4872-4878. (doi:10.1210/jc.2001-011766).
136. Giordano R, Marinazzo E, Berardelli R, Picu A, Maccario M, Ghigo E & Arvat E. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. European Journal of Endocrinology 2010 162 779-785. (doi:10.1530/EJE-09-0957).
137. Masserini B, Morelli V, Palmieri S, Eller-Vainicher C, Zhukouskaya V, Cairoli E, Orsi E, Beck-Peccoz P, Spada A & Chiodini I. Lipid abnormalities in patients with adrenal incidentalomas: role of subclinical hypercortisolism and impaired glucose metabolism. Journal of Endocrinological Investigation 2015 38 623-628. (doi:10.1007/s40618-014-0232-0).
138. Fardet L, Cabane J, Kettaneh A, Lebbe C & Flahault A. Corticosteroidinduced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology 2007 46 1102-1106. (doi:10.1093/rheumatology/kem062).
139. Choi HK & Seeger JD. Glucocorticoid use and serum lipid levels in US adults: The Third National Health and Nutrition Examination Survey. Arthritis and Rheumatism 2005 53 528-535. (doi:10.1002/art.21329).
140. Xu C, He J, Jiang H, Zu L, Zhai W, Pu S & Xu G. Direct effect of glucocorticoids on lipolysis in adipocytes. Molecular Endocrinology 2009 23 1161-1170. (doi:10.1210/me.2008-0464).
141. Shen WJ, Patel S, Miyoshi H, Greenberg AS & Kraemer FB. Functional interaction of hormone-sensitive lipase and perilipin in lipolysis. Journal of Lipid Research 2009 50 2306-2313. (doi:10.1194/jlr. M900176-JLR200).
142. Appel B & Fried SK. Effects of insulin and dexamethasone on lipoprotein lipase in human adipose tissue. American Journal of Physiology 1992 262 E695-E699.
143. Fried SK, Russell CD, Grauso NL & Brolin RE. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. Journal of Clinical Investigation 1993 92 2191-2198. (doi:10.1172/JCI116821).
144. Ottosson M, Vikman-Adolfsson K, Enerback S, Olivecrona G & Bjorntorp P. The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. Journal of Clinical Endocrinology and Metabolism 1994 79 820-825. (doi:10.1210/jcem.79.3.8077367).
145. Campbell JE, Peckett AJ, D'Souza AM, Hawke TJ & Riddell MC. Adipogenic and lipolytic effects of chronic glucocorticoid exposure. American Journal of Physiology. Cell Physiology 2011 300 C198-C209. (doi:10.1152/ajpcell.00045.2010).
146. Bagdade JD, Yee E, Albers J & Pykalisto OJ. Glucocorticoids and triglyceride transport: effects on triglyceride secretion rates, lipoprotein lipase, and plasma lipoproteins in the rat. Metabolism: Clinical and Experimental 1976 25 533-542. (doi:10.1016/0026-0495(76)90007-X).
147. Manenschijn L, van den Akker EL, Lamberts SW & van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Annals of the New York Academy of Sciences 2009 1179 179-198. (doi:10.1111/j.1749-6632.2009.05013.x).
148. Morton NM. Obesity and corticosteroids: 11b-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Molecular and Cellular Endocrinology 2010 316 154-164. (doi:10.1016/j.mce. 2009.09.024).
149. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV et al. The 11-b-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010 33 1516-1522. (doi:10.2337/dc09-2315).
150. Gylling H, Vanhanen H & Miettinen TA. Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia. Journal of Lipid Research 1993 34 59-67.
151. Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR & Besser GM. Possible mechanism and treatment of o, p'DDD-induced hypercholesterolaemia. Quarterly Journal of Medicine 1992 84 671-679.
152. Neuvonen PJ, Niemi M & Backman JT. Drug interactions with lipidlowering drugs: mechanisms and clinical relevance. Clinical Pharmacology and Therapeutics 2006 80 565-581. (doi:10.1016/j.clpt. 2006.09.003).
153. Vakili H & Cattini PA. The hidden but positive role for glucocorticoids in the regulation of growth hormone-producing cells. Molecular and Cellular Endocrinology 2012 363 1-9. (doi:10.1016/j.mce.2012.08.001).
154. Jain V, Metherell LA, David A, Sharma R, Sharma PK, Clark AJ & Chan LF. Neonatal presentation of familial glucocorticoid deficiency resulting from a novel splice mutation in the melanocortin 2 receptor accessory protein. European Journal of Endocrinology 2011 165 987-991. (doi:10.1530/EJE-11-0581).
155. McEachern R, Drouin J, Metherell L, Huot C, Van Vliet G & Deal C. Severe cortisol deficiency associated with reversible growth hormone deficiency in two infants: what is the link? Journal of Clinical Endocrinology and Metabolism 2011 96 2670-2674. (doi:10.1210/jc. 2011-0129).
156. Pekic S, Doknic M, Djurovic M, Damjanovic S, Petakov M, Miljic D, Dieguez C, Casanueva FF & Popovic V. The influence of serum cortisol levels on growth hormone responsiveness to GH-releasing hormone plus GH-releasing peptide-6 in patients with hypocortisolism. Hormones 2003 2 243-249. (doi:10.14310/horm.2002.11106).
157. Casanueva FF, Burguera B, Muruais C & Dieguez C. Acute administration of corticoids: A new and peculiar stimulus of growth hormone secretion in man. Journal of Clinical Endocrinology and Metabolism 1990 70 234-237. (doi:10.1210/jcem-70-1-234).
158. Krogh J, Nordentoft M, Mohammad-Nezhad M & Westrin A. Growth hormone, prolactin and cortisol response to exercise in patients with depression. Journal of Affective Disorders 2010 125 189-197. (doi:10.1016/j.jad.2010.01.009).
159. Storr HL, Chan LF, Grossman AB & Savage MO. Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends in Endocrinology and Metabolism 2007 18 167-174. (doi:10.1016/j.tem.2007.03.005).
160. Carroll PV, Monson JP, Grossman AB, Besser GM, Plowman PN, Afshar F & Savage MO. Successful treatment of childhood-onset Cushing's disease is associated with persistent reduction in growth hormone secretion. Clinical Endocrinology 2004 60 169-174. (doi:10.1046/j.1365-2265.2003.01922.x).
161. Tzanela M, Karavitaki N, Stylianidou C, Tsagarakis S & Thalassinos NC. Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome. Clinical Endocrinology 2004 60 309-314. (doi:10.1046/j.1365-2265.2004. 01976.x).
162. Feldt-Rasmussen U, Abs R, Bengtsson BA, Bennmarker H, Bramnert M, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P, Wuster C et al. Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. European Journal of Endocrinology 2002 146 67-74. (doi:10.1530/eje.0. 1460067).
163. van Aken MO, Pereira AM, Frolich M, Romijn JA, Pijl H, Veldhuis JD & Roelfsema F. Growth hormone secretion in primary adrenal Cushing's syndrome is disorderly and inversely correlated with body mass index. American Journal of Physiology. Endocrinology and Metabolism 2005 288 E63-E70. (doi:10.1152/ajpendo.00317.2004).
164. Pecori Giraldi F, Andrioli M, De Marinis L, Bianchi A, Giampietro A, De Martin M, Sacco E, Scacchi M, Pontecorvi A & Cavagnini F. Significant GH deficiency after long-term cure by surgery in adult patients with Cushing's disease. European Journal of Endocrinology 2007 156 233-239. (doi:10.1530/eje.1.02329).
165. Palmieri S, Morelli V, Salcuni AS, Eller-Vainicher C, Cairoli E, Zhukouskaya VV, Beck-Peccoz P, Scillitani A & Chiodini I. GH secretion reserve in subclinical hypercortisolism. Pituitary 2014 17 470-476. (doi:10.1007/s11102-013-0528-7).
166. Mazziotti G & Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nature Reviews. Endocrinology 2013 9 265-276. (doi:10.1038/nrendo.2013.5).
167. Lui JC, Nilsson O & Baron J. Growth plate senescence and catch-up growth. Endocrine Development 2011 21 23-29. (doi:10.1159/000328117).
168. Arnaldi G, Mancini T, Tirabassi G, Trementino L & Boscaro M. Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications. Journal of Endocrinological Investigation 2012 35 434-448. (doi:10.1007/BF03345431).
169. Davies JH, Storr HL, Davies K, Monson JP, Besser GM, Afshar F, Plowman PN, Grossman AB & Savage MO. Final adult height and body mass index after cure of paediatric Cushing's disease. Clinical Endocrinology 2005 62 466-472. (doi:10.1111/j.1365-2265.2005. 02244.x).
170. Lebrethon MC, Grossman AB, Afshar F, Plowman PN, Besser GM & Savage MO. Linear growth and final height after treatment for Cushing's disease in childhood. Journal of Clinical Endocrinology and Metabolism 2000 85 3262-3265. (doi:10.1210/jcem.85.9.6817).
171. Webb SM, Mo D, Lamberts SW, Melmed S, Cavagnini F, Pecori Giraldi F, Strasburger CJ, Zimmermann AG & Woodmansee WW. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or nonfunctioning pituitary adenoma. Journal of Clinical Endocrinology and Metabolism 2010 95 630-638. (doi:10.1210/jc.2009-0806).
172. Johannsson G, Sunnerhagen KS & Svensson J. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. Clinical Endocrinology 2004 60 550-559. (doi:10. 1111/j.1365-2265.2004.02018.x).
173. Magiakou MA, Smyrnaki P & Chrousos GP. Hypertension in Cushing's syndrome. Best Practice & Research. Clinical Endocrinology & Metabolism 2006 20 467-482. (doi:10.1016/j.beem.2006.07.006).
174. Cicala MV & Mantero F. Hypertension in Cushing's syndrome: From pathogenesis to treatment. Neuroendocrinology 2010 92 (Suppl 1) 44-49. (doi:10.1159/000314315).
175. Sato A, Suzuki H, Murakami M, Nakazato Y, Iwaita Y & Saruta T. Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 1994 23 25-30. (doi:10.1161/01.HYP.23.1.25).
176. Kelly JJ, Martin A & Whitworth JA. Role of erythropoietin in cortisolinduced hypertension. Journal of Human Hypertension 2000 14 195-198. (doi:10.1038/sj.jhh.1000959).
177. Kirilov G, Tomova A, Dakovska L, Kumanov P, Shinkov A & Alexandrov AS. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. European Journal of Endocrinology 2003 149 549-553. (doi:10.1530/eje. 0.1490549).
178. Smith L & Smith JB. Regulation of sodium-calcium exchanger by glucocorticoids and growth factors in vascular smooth muscle. Journal of Biological Chemistry 1994 269 27527-27531.
179. Sala C, Ambrosi B & Morganti A. Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with cushing's disease. Journal of Clinical Endocrinology and Metabolism 2001 86 1957-1961. (doi:10.1210/jcem.86.5.7477).
180. Wallerath T, Witte K, Schafer SC, Schwarz PM, Prellwitz W, Wohlfart P, Kleinert H, Lehr HA, Lemmer B & Forstermann U. Downregulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. PNAS 1999 96 13357-13362. (doi:10.1073/pnas.96.23.13357).
181. Mitchell BM, Dorrance AM, Mack EA & Webb RC. Glucocorticoids decrease GTP cyclohydrolase and tetrahydrobiopterin-dependent vasorelaxation through glucocorticoid receptors. Journal of Cardiovascular Pharmacology 2004 43 8-13. (doi:10.1097/00005344- 200401000-00002).
182. Rizzoni D, Porteri E, De Ciuceis C, Rodella LF, Paiardi S, Rizzardi N, Platto C, Boari GE, Pilu A, Tiberio GA et al. Hypertrophic remodeling of subcutaneous small resistance arteries in patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2009 94 5010-5018. (doi:10.1210/jc.2009-1588).
183. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: A clinical review. Journal of Hypertension 2006 24 983-991. (doi:10.1097/01.hjh.0000226182. 60321.69).
184. Karamouzis I, Berardelli R, D'Angelo V, Fussotto B, Zichi C, Giordano R, Settanni F, Maccario M, Ghigo E & Arvat E. Enhanced oxidative stress and platelet activation in patients with Cushing's syndrome. Clinical Endocrinology 2015 82 517-524. (doi:10.1111/cen.12524).
185. Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, Durmus I, Korkmaz L & Celik S. Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing's Syndrome. Endocrine 2007 31 300-304. (doi:10.1007/s12020-007-0033-8).
186. Akaza I, Yoshimoto T, Tsuchiya K & Hirata Y. Endothelial dysfunction aassociated with hypercortisolism is reversible in Cushing's syndrome. Endocrine Journal 2010 57 245-252. (doi:10.1507/endocrj. K09E-260).
187. Albiger N, Testa RM, Almoto B, Ferrari M, Bilora F, Petrobelli F, Pagnan A, Mantero F & Scaroni C. Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Hormone and Metabolic Research 2006 38 405-410. (doi:10.1055/s-2006-944545).
188. Barahona MJ, Resmini E, Vilades D, Pons-Llado G, Leta R, Puig T & Webb SM. Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2013 98 1093-1099. (doi:10.1210/jc.2012-3547).
189. Fallo F, Famoso G, Capizzi D, Sonino N, Dassie F, Maffei P, Martini C, Paoletta A, Iliceto S & Tona F. Coronary microvascular function in patients with Cushing's syndrome. Endocrine 2013 43 206-213. (doi:10.1007/s12020-012-9764-2).
190. Debono M, Bradburn M, Bull M, Harrison B, Ross RJ & Newell-Price J. Cortisol as amarker for increased mortality in patients with incidental adrenocortical adenomas. Journal of Clinical Endocrinology and Metabolism 2014 99 4462-4470. (doi:10.1210/jc.2014-3007).
191. Iacobellis G, Petramala L, Barbaro G, Kargi AY, Serra V, Zinnamosca L, Colangelo L, Marinelli C, Ciardi A, De Toma G et al. Epicardial fat thickness and left ventricular mass in subjects with adrenal incidentaloma. Endocrine 2013 44 532-536. (doi:10.1007/s12020-013- 9902-5).
192. Bassareo PP, Fanos V, Zaffanello M & Mercuro G. Early markers of cardiovascular dysfunction in young girls affected by Cushing's syndrome before and after successful cure. Journal of Pediatric Endocrinology & Metabolism 2010 23 627-635. (doi:10.1515/jpem. 2010.103).
193. Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD & Geer EB. Predictors of mortality and long-term outcomes in treated Cushing's disease: A study of 346 patients. Journal of Clinical Endocrinology and Metabolism 2013 98 1022-1030. (doi:10.1210/jc.2012-2893).
194. Chow JT, Thompson GB, Grant CS, Farley DR, Richards ML & Young WF Jr. Bilateral laparoscopic adrenalectomy for corticotrophindependent Cushing's syndrome: A review of the Mayo Clinic experience. Clinical Endocrinology 2008 68 513-519. (doi:10.1111/j. 1365-2265.2007.03082.x).
195. Iacobone M, Citton M, Scarpa M, Viel G, Boscaro M & Nitti D. Systematic review of surgical treatment of subclinical Cushing's syndrome. British Journal of Surgery 2015 102 318-330. (doi:10.1002/bjs.9742).
196. Dekkers OM, Horvath-Puho E, Jorgensen JO, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, Pereira AM & Sorensen HT. Multisystem morbidity and mortality in Cushing's syndrome: A cohort study. Journal of Clinical Endocrinology and Metabolism 2013 98 2277-2284. (doi:10.1210/jc.2012-3582).
197. Isidori AM, Graziadio C, Paragliola RM, Cozzolino A, Ambrogio AG, Colao A, Corsello SM, Pivonello R & ABC Study Group. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. Journal of Hypertension 2015 33 44-60. (doi:10.1097/HJH.0000000000000415).
198. Nieman LK. Medical therapy of Cushing's disease. Pituitary 2002 5 77-82. (doi:10.1023/A:1022308429992).
199. Donadille B, Groussin L, Waintrop C, Abbas H, Tenenbaum F, Dugue MA, Coste J, Bertagna X & Bertherat J. Management of Cushing's syndrome due to ectopic adrenocorticotropin secretion with 1, ortho-1, para'-dichloro-diphenyl-dichloro-ethane: Findings in 23 patients from a single center. Journal of Clinical Endocrinology and Metabolism 2010 95 537-544. (doi:10.1210/jc.2009-1317).
200. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C & Investigators SS. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 2012 97 2039-2049. (doi:10.1210/jc.2011-3350).
201. Castinetti F, Brue T & Conte-Devolx B. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome. Current Opinion in Endocrinology, Diabetes, and Obesity 2012 19 295-299. (doi:10.1097/MED.0b013e32835430bf).
202. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM et al. A 12-month phase 3 study of pasireotide in Cushing's disease. New England Journal of Medicine 2012 366 914-924. (doi:10.1056/NEJMoa1105743).
203. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. New England Journal of Medicine 2010 362 1846-1848. (doi:10.1056/NEJMc1000094).
204. Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, Scaroni C, Arvat E, Pontecorvi A & Cavagnini F. Potential role for retinoic acid in patients with Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2012 97 3577-3583. (doi:10.1210/jc.2012-2328).
205. Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, Watson CE, Maldonado M, Hamrahian AH, Boscaro M et al. LCI699, a potent 11b-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proofof- concept study. Journal of Clinical Endocrinology and Metabolism 2014 99 1375-1383. (doi:10.1210/jc.2013-2117).
206. Wajchenberg BL, Bosco A, Marone MM, Levin S, Rocha M, Lerario AC, Nery M, Goldman J & Liberman B. Estimation of body fat and lean tissue distribution by dual energyX-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. Journal of Clinical Endocrinology and Metabolism 1995 80 2791-2794. (doi:10.1210/jcem.80.9.7673425).
207. Mills GH, Kyroussis D, Jenkins P, Hamnegard CH, Polkey MI, Wass J, Besser GM, Moxham J & Green M. Respiratory muscle strength in Cushing's syndrome. American Journal of Respiratory and Critical Care Medicine 1999 160 1762-1765. (doi:10.1164/ajrccm.160.5.9810028).
208. Minetto MA, Lanfranco F, Botter A, Motta G, Mengozzi G, Giordano R, Picu A, Ghigo E & Arvat E. Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing's disease European Journal of Endocrinology 2011 164 985-993. (doi:10.1530/EJE- 10-1169).
209. Anagnos A, Ruff RL & Kaminski HJ. Endocrine neuromyopathies. Neurologic Clinics 1997 15 673-696. (doi:10.1016/S0733- 8619(05)70339-X).
210. Minetto MA, Qaisar R, Agoni V, Motta G, Longa E, Miotti D, Pellegrino MA & Bottinelli R. Quantitative and qualitative adaptations of muscle fibers to glucocorticoids. Muscle & Nerve, 2015. In press. (doi:10.1002/mus.24572).
211. Schakman O, Kalista S, Barbe C, Loumaye A & Thissen JP. Glucocorticoid- induced skeletal muscle atrophy. International Journal of Biochemistry & Cell Biology 2013 45 2163-2172. (doi:10.1016/j.biocel. 2013.05.036).
212. Croxtall JD, van Hal PT, Choudhury Q, Gilroy DW & Flower RJ. Different glucocorticoids vary in their genomic and non-genomic mechanismof action in A549 cells. British Journal of Pharmacology 2002 135 511-519. (doi:10.1038/sj.bjp.0704474).
213. Alshekhlee A, Kaminski HJ & Ruff RL. Neuromuscular manifestations of endocrine disorders. Neurologic Clinics 2002 20 35-58, v-vi. (doi:10.1016/S0733-8619(03)00053-7).
214. Kilgour AH, Gallagher IJ, MacLullich AM, Andrew R, Gray CD, Hyde P, Wackerhage H, HusiH, Ross JA, Starr JM et al. Increased skeletal muscle 11bHSD1 mRNA is associated with lower muscle strength in ageing. PLoS ONE 2013 8 e84057. (doi:10.1371/journal.pone.0084057).
215. Pereira RM & Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint, Bone, Spine 2011 78 41-44. (doi:10.1016/j.jbspin.2010.02.025).
216. Liu Z, Li G, Kimball SR, Jahn LA & Barrett EJ. Glucocorticoids modulate amino acid-induced translation initiation in human skeletal muscle. American Journal of Physiology. Endocrinology and Metabolism 2004 287 E275-E281. (doi:10.1152/ajpendo.00457.2003).
217. Son YH, Lee SJ, Lee KB, Lee JH, Jeong EM, Chung SG, Park SC & Kim IG. Dexamethasone downregulates caveolin-1 causing muscle atrophy via inhibited insulin signaling. Journal of Endocrinology 2015 225 27-37. (doi:10.1530/JOE-14-0490).
218. Hasselgren PO. Glucocorticoids and muscle catabolism. Current Opinion in Clinical Nutrition and Metabolic Care 1999 2 201-205. (doi:10.1097/00075197-199905000-00002).
219. Inder WJ, Jang C, Obeyesekere VR & Alford FP. Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1 - implications for steroid-induced myopathy. Clinical Endocrinology 2010 73 126-132. (doi:10.1111/j.1365-2265. 2009.03683.x).
220. McCroskery S, Thomas M, Maxwell L, Sharma M & Kambadur R. Myostatin negatively regulates satellite cell activation and selfrenewal. Journal of Cell Biology 2003 162 1135-1147. (doi:10.1083/jcb. 200207056).
221. Welle S, Bhatt K & Pinkert CA. Myofibrillar protein synthesis in myostatin-deficient mice. American Journal of Physiology. Endocrinology and Metabolism 2006 290 E409-E415. (doi:10.1152/ajpendo.00433. 2005).
222. Mitsui T, Azuma H, Nagasawa M, Iuchi T, Akaike M, Odomi M & Matsumoto T. Chronic corticosteroid administration causes mitochondrial dysfunction in skeletal muscle. Journal of Neurology 2002 249 1004-1009. (doi:10.1007/s00415-002-0774-5).
223. Ralliere C, Tauveron I, Taillandier D, Guy L, Boiteux JP, Giraud B, Attaix D & Thieblot P. Glucocorticoids do not regulate the expression of proteolytic genes in skeletal muscle from Cushing's syndrome patients. Journal of Clinical Endocrinology and Metabolism 1997 82 3161-3164. (doi:10.1210/jcem.82.9.4221).
224. Dong Y, Silva KA, Dong Y & Zhang L. Glucocorticoids increase adipocytes in muscle by affecting IL-4 regulated FAP activity. FASEB Journal 2014 28 4123-4132. (doi:10.1096/fj.14-254011).